News
-
-
-
-
PRESS RELEASE
Very successful human clinical trial with the innovative antibacterial surface-treated implants receives approval for quick end of recruitment.
Successful early termination of human clinical trial by aap Implantate AG for antibacterial implants with excellent results, approved by regulatory authorities -
-
PRESS RELEASE
aap Implantate AG: annual financial statements 2023 characterized by the difficult economic environment and restructuring measures introduced, good operational progress
aap Implantate AG's annual financial statements for 2023 show progress despite economic challenges and restructuring efforts. Sales increased initially but faced obstacles later -
-
PRESS RELEASE
EQS-Adhoc: aap Implantate AG: Auditor will terminate audit and declare non-issuance of audit opinion due to audit impediments
aap Implantate AG's auditor Baker Tilly GmbH & Co KG will not issue an opinion on the annual financial statements due to audit impediments. The Company faces potential penalty and is resolving issues for future audits -
-
PRESS RELEASE
Half-year financial statements close with balanced EBITDA, Trauma with positive EBITDA
aap Implantate AG reports balanced EBITDA with positive results in trauma business for the first half of 2024. Sales increased by 10% to EUR 6.4 million, driven by EMEA region growth. Key figures include stable gross margin and improved EBITDA
